🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL NCT06489808Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Linperlisib, Rituximab, Gemcitabine, Oxaliplatin, Ifosfamide CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. NCT07538635Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Axicabtagene Ciloleucel Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma NCT07524816n/a1 site📍 Lyasny N.N. Alexandrov National Cancer Centre · Tests: CAR-T cell therapy Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma NCT06905509Phase 21 site📍 Sacramento University of California, Davis · Tests: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine, Dexamethasone, Epcoritamab A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma NCT07823829Phase 1, Phase 23 sites📍 Shanghai📍 Shanghai📍 Hubei UCARsgen Biotech Limited · Tests: CT1190B intravenous infusion Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL NCT06104592Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma NCT07788118Phase 1, Phase 21 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: 7×19-THEMIS CAR-T cells Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL NCT06526793Phase 294 sites📍 Phoenix📍 Duarte📍 Jacksonville AstraZeneca · Tests: Surovatamig CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma NCT06479356Phase 21 site📍 Tianjin Shanghai Ming Ju Biotechnology Co., Ltd. · Tests: Relma-cel Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients NCT04844866Phase 251 sites📍 Graz📍 Innsbruck📍 Linz Miltenyi Biomedicine GmbH · Tests: MB-CART2019.1, Standard of Care The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study NCT07240194Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Glofitamab, PD-1 Inhibitor, Lenalidomide, Obinutuzumab A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites📍 La Jolla📍 Boston📍 Rochester AstraZeneca · Tests: AZD5492
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy